Abstract:

Objective: Clinically, there is an urgent need for small-diameter artificial vascular grafts (SDAVGs) meeting the requirements of rapid endothelialization and thrombotic resistance, and poor vascular remodeling is one of the bottlenecks affecting the clinical transformation of SDAVGs. This study aims to design and fabricate a three-layer biomimetic SDAVG,and utilize single cell RNA-sequencing to explore the mechanism of the vascular remodeling after SDAVG implantation.Methods: To ensure the safety of the novel three-layer biomimetic SDAVGs in vivo, we evaluated their biocom- patibility and hemocompatibility firstly. Then, a porcine carotid artery replacement model was established to analyze the biological performance of the three-layer biomimetic small-diameter artificial vascular graft, and histopathological analysis of tissue sections of vascular grafts was performed by HE and immunohistochemi- cal staining. Additionally, single cell transcriptome sequencing was used to investigate the cell composition and changes after blood vessel implantation.Results: In all in vitro experiments, the small-diameter artificial blood vessel exhibited excellent biocompatibility and hemocompatibility. Furthermore, in vivo transplantation experiments demonstrated favorable anti-throm- botic properties and minimal intimal hyperplasia. And the small-diameter artificial blood caused no evident inflammatory reaction in tissue in vivo implantation experiments. What’s more, single-cell RNA sequencing revealed that endothelial cells (ECs), vascular smooth cells (SMCs), and myeloid cells were the main cell type in the small-diameter artificial blood, and endothelial-to-mesenchymal transition (EndMT) occurred. RNA velocity showed that ECs subtype transitions from quiescent to proliferating phenotype (Figure 1).

Abstract:

Title: Perivenular intracavernosal Mesenchymal stem cell ( MSC ) Isolation and storage from Corpora caverno- sum and corpora spongiosum in adult male rabbit and adult dog and production of clonal MSC nanoparticu- lated delivery for penile condition which caused ED ( Erectile dysfunction ) in subject male rabbit and dog and check for the erection function in these male Dog and Rabbit.AIM: To prove the association of whether clonal MSC produced in GMP grade facility has role in ED treatment has value in regenerative medicine practice in Animals and thereby in humans. Methodology: Taking 20 dogs and Rabbit as control and 20 as subjects ( Dogs/ rabbit) DMED ( Stretozocin induced diabetic ED) Male Dogs and Male Rabbits, they are subjected to clonal delivery of nanoparticulated MSC ( Mesenchymal Stem Cells ) . The ED function can be measured by intra cavernosal pressure measure- ment, apomorphine test, dynamic infusion caversometry, isometric tension study. The to be Stored MSC can be isolated and expanded in culture medium . After extraction these MSC cells are expanded to estimate the cytokine and biological response modifier functions and see for cytokine levels and regeneration mechanisms.Discussion: The nanoparticulated Intracavernosal delivery of MSC can be used if proven superior and can be apotential treatment modality form DMED dogs and Rabbit Model.

Abstract:

Background: This study aimed to evaluate the safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (allo-ASC) for the treatment of lateral epicondylosis (LE). Mesenchymal stem cell therapy presents a promising regenerative treatment for tendinopathy, and this trial sought to compare intra-tendon injections of allo-ASC against a control treatment.Methods: Ten patients with LE persisting for over six months were recruited and randomly assigned to either the cell group or control group. Injections were performed under sonographic guidance, delivering 0.5 ml of thrombin with 10^6 allo-ASCs (cell group) or normal saline (control group) mixed with 0.5 ml of fibrin into the largest hypoechoic defect in the common extensor tendon. Safety assessments were conducted on day 3, and at 2, 6, 12, 24, and 48 weeks post-injection. Efficacy was measured using pain visual analogue scale (VAS) at rest and during activity, Mayo elbow performance index (MEPI), grip strength, and ultrasonographic evaluations at baseline and at 6, 12, 24 and 48 weeks post-injection. Ultrasonographic findings were rated using a 5-point Likert scale. An intention-to-treat analysis with the last observation carried forward method was employed.Results: Five patients were assigned to the cell group and five to the control group. One control group patient dropped out before the 48-week follow-up due to aggravated calcific tendinitis of the elbow. No serious adverse events were reported. Both groups showed significant improvement in pain VAS at rest and MEPI from baseline to 48 weeks. The cell group also showed significant improvement in pain VAS during activity and grip strength, while the control group did not exhibit significant changes in these measures. No statistically significant differ- ences were observed between the groups at any follow-up point.

Abstract:

Stem cells are increasingly used to model human disorders, employed as a tool in drug discovery and lever- aged for their therapeutic value. In our lab, we have successfully developed stem cell-derived organoids or 3D cultures of the miniature liver, brain, and cartilage along with cancer stem cell models to explore many aspects of biology- molecular and cellular mechanisms, drug testing systems and transplantable cellular resources. From the perspective of regenerative medicine for developing treatment for aging associated diseases, we have developed a multiple-cell system using stem cells to study both degenerative diseases and characterise the therapeutic value of stem cells as single and combination therapy as potential treatment modalities for var- ious degenerative conditions. In order to make stem cell transplantation a success, we have been developing rejuvenation strategies for ageing stem cells and expanding their therapeutic value by improving the stem cell bioprocessing pipeline in collaboration with industrial partners. While one arm of the lab is focusing on regen- erative medicine, the other arm is dedicated to developing cancer stem cell models and key regulatory targets through integrated multi-omic bioinformatics analysis and targeted regulators that will enable the targeting of the resistant population in a tumour, therefore eradicating cancer. In this talk, I will highlight how we can lever- age stem cell biology to understand disease mechanisms, modelling the diseases and leverage their potential for realising regenerative medicine, along with how stem cell may answer some of your research questions and produce a work with high scientific merit.